Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05077709 · ClinicalTrials.gov registry record · Phase 2

IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

A Phase 2 study of Head and Neck Squamous Cell Carcinoma and Urothelial Carcinoma Bladder, sponsored by IO Biotech.

Active
Registry status
Phase 2
Development phase
63
Enrollment target
20
Study locations

NCT05077709 is a Phase 2 study of Head and Neck Squamous Cell Carcinoma and Urothelial Carcinoma Bladder that is active but no longer recruiting, run by IO Biotech. The registered enrollment target is 63 participants, below the 117-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (46% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05077709, a Phase 2 study of Head and Neck Squamous Cell Carcinoma and Urothelial Carcinoma Bladder, is active but no longer recruiting, sponsored by IO Biotech.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
63 participants
Enrollment target
20
Study locations

Study Summary

A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head or Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)

Conditions Studied

Head and Neck Squamous Cell Carcinoma Urothelial Carcinoma Bladder Lung Cancer, Non-Small Cell

Interventions

  • DRUG IO102-IO103 in combination with pembrolizumab

Study Locations (20)

Other

  • Hospital Vall d'Hebron - Barcelona
  • Institut Català d'Oncologia (ICO) Badalona (Catalan Institute of Oncology) - Barcelona
  • Hospital Universitari de Girona Doctor Josep Trueta - Girona
  • Hospital Universitario Ramon y Cajal - Madrid
  • Hospital Universitario Fundación Jiménez Díaz - Madrid
  • Hospital Universitario 12 de Octubre - Madrid
  • Hospital Universitario Virgen de la Victoria - Málaga
  • Hospital Universitario Virgen Macarena - Seville
  • Hospital Clínico Universitario de Valencia - Valencia
  • Hospital Clínico Lozano Blesa - Zaragoza
  • Velindre Cancer Center - Cardiff

California

  • City of Hope - Duarte
  • UC Davis Cancer Center - Sacramento
  • University of California San Diego - San Diego

Florida

  • Mid Florida Hematology and Oncology Center - Orange City

New York

  • Montefiore Medical Center - The Bronx

Ohio

  • University of Toledo Medical Center - Toledo

Oregon

  • Oregon Health & Science University - Portland

Pennsylvania

  • University of Pennsylvania - Philadelphia

Virginia

  • Virginia Cancer Specialists - Fairfax

Trial Details

FieldValue
Enrollment Target 63 participants
Start Date 2022-02-14
Est. Completion 2024-11-30
Phase Phase 2

Sponsor

IO Biotech

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05077709

The ClinicalTrials.gov registry entry for NCT05077709 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 117-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (46% lower). The listed sponsor is IO Biotech, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Head and Neck Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which IO102-IO103 in combination with pembrolizumab is the first listed.

NCT05077709 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, California, Florida.

Frequently Asked Questions

What is clinical trial NCT05077709 about?

NCT05077709 is a clinical study titled "IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC". A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head or Neck (SCCHN), or Metastatic Urothelial Bladder Cance...

What is the current status of trial NCT05077709?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2022-02-14. Estimated completion is 2024-11-30.

What conditions does trial NCT05077709 study?

This clinical trial studies the following conditions: Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder, Lung Cancer, Non-Small Cell.

What interventions are being tested in trial NCT05077709?

The interventions under investigation include: IO102-IO103 in combination with pembrolizumab (DRUG).

Who is sponsoring clinical trial NCT05077709?

This trial is sponsored by IO Biotech, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05077709 being conducted?

This trial has 20 study locations across California, Florida, New York, Ohio, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Squamous Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Head and Neck Squamous Cell Carcinoma

All registered trials for this condition

Urothelial Carcinoma Bladder

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.